The findings, published in Nature Communications, focus on the transparent cornea, an organ where stem-cell failure can lead to severe visual impairment. Using a multicolor fluorescent labeling system, the team tracked stem-cell dynamics in living mice and then experimentally eliminated native stem cells to test whether the tissue could still restore function.

Prof. Ruby Shalom-Feuerstein and Dr. Shalini Dimri-Wagh describe a key surprise: even after all corneal stem cells are destroyed, the tissue retains the capacity to regenerate. More importantly, the repair process does not depend on a brief, temporary shift in identity. Instead, reprogrammed cells behave like bona fide stem cells over extended periods, supporting long-term homeostasis and reducing the likelihood of progressive disease.

Mechanistically, the work points to the immune microenvironment as the driver of cellular “time reversal.” In particular, macrophages—normally associated with clearing pathogens and orchestrating inflammation—also produce niche cytokines and signaling molecules that coax aged differentiated cells back toward stemness.

This immune-mediated reprogramming reframes regeneration as a controlled re-entry into a native state, guided by local signals. Rather than treating tissue failure as an endpoint that demands replacement, the results argue that endogenous repair pathways can be activated from within.

Because corneal stem cells are central to maintaining transparency and epithelial renewal, the translational implications are substantial. The authors note that experiments were primarily conducted in mice, but data from human corneal cells are reported as encouraging.

The team’s next priority is control—determining how to trigger the reprogramming program safely and reliably in humans, and how to harness it for regenerative medicine. If achievable, therapies could aim to amplify the body’s own regeneration machinery, potentially reducing dependence on donor tissue.

The study also adds a broader biological insight: while complex organisms may have lost the ability to regrow whole organs, they still preserve partial regenerative capacity. In this view, the “lost” potential may remain latent, waiting for the right immune and cytokine cues.

Subject of Research: Animals

Article Title: Aged differentiated cells reverse into native stemness-like state by niche cytokines to sustain lifelong homeostasis and tissue repair

News Publication Date: 25-Apr-2026

Web References: http://dx.doi.org/10.1038/s41467-026-72331-w

References: Nature Communications (25-Apr-2026); DOI: 10.1038/s41467-026-72331-w

Image Credits: Not provided

Keywords: Regenerative medicine, Stem cells, Cell biology, Ophthalmology, Immunology, Tissue engineering, Translational research

Traditionally, ESC culture methods have been optimized for model organisms like mice, with protocols often failing when applied to other mammals, including humans and livestock. The new 6iL/E4 system circumvents these challenges by finely tuning the cellular environment through a combination of six small-molecule inhibitors (“6i”), leukemia inhibitory factor (LIF), and the addition of the E4 supplement. This synergy ensures the maintenance of pluripotency and self-renewal capabilities across multiple mammalian lineages.

At the heart of the 6iL/E4 medium are the six inhibitors, each targeting key signaling pathways that regulate stem cell differentiation, proliferation, and survival. By inhibiting pathways such as ERK, GSK3, and PKC, the system tightly controls the cellular milieu to maintain cells in a ground-state pluripotent condition. The LIF element provides additional support by activating the JAK/STAT pathway, essential for self-renewal, while the E4 component supplies crucial growth factors and nutrients, further refining the culture conditions.

This universal platform was rigorously tested on embryonic stem cells derived from a spectrum of mammalian species, including rodents, primates, and ungulates. Remarkably, ESCs cultured in 6iL/E4 retained hallmark features of pluripotency, expressed typical stem cell markers, and displayed robust proliferation over extended periods. The researchers also demonstrated that these cells retained full developmental potential, laying the groundwork for species-transcending applications.

The implications of this breakthrough are vast. By providing a standardized culture environment, 6iL/E4 facilitates comparative studies of embryonic development and evolutionary biology. Moreover, it accelerates the advent of personalized regenerative therapies across different species, including endangered animals and agricultural mammals. The universal nature of the system could simplify stem cell banking and genetic engineering efforts, drastically reducing costs and variability.

Furthermore, 6iL/E4 promises to streamline drug discovery and toxicity testing by enabling the cultivation of physiologically relevant ESCs from various species, broadening the scope of translational research without relying exclusively on human samples. This universality may also enhance the reproducibility of experiments, a critical factor for clinical translation.

While the 6iL/E4 culture system represents a significant leap forward, the study’s authors highlight the need for further research to optimize the medium for later stages of differentiation specific to each species. Understanding the nuanced developmental cues remains paramount to fully harnessing the potential of cross-species stem cell applications.

In sum, the emergence of 6iL/E4 heralds a new era where the challenges of species-specific pluripotency maintenance are addressed by a single, robust culture medium. This advancement not only enriches fundamental biological understanding but also sets the stage for transformative applications in medicine, agriculture, and conservation.

Subject of Research: Development of a universal culture system for embryonic stem cells across mammalian species

Article Title: A universal 6iL/E4 culture system for deriving and maintaining embryonic stem cells across mammalian species

Article References:
Wang, D., Ming, H., Yang, D. et al. A universal 6iL/E4 culture system for deriving and maintaining embryonic stem cells across mammalian species. Cell Res (2026). https://doi.org/10.1038/s41422-026-01276-y

DOI: https://doi.org/10.1038/s41422-026-01276-y

ISSCR 2026 serves as a vibrant platform for showcasing nearly 1,300 scientific posters and presentations that span the full spectrum of stem cell research. Attendees gain access to breakthrough discoveries, emerging technologies, and innovative methodologies shaping the future of biomedical science. The conference fosters interdisciplinary collaboration among scientists, clinicians, ethicists, and industry leaders, creating fertile ground for cross-pollination of ideas and accelerating translational impact.

The opening plenary, curated by ISSCR President Hideyuki Okano, set an inspiring tone by featuring pioneers whose research has fundamentally transformed the field. Nobel Laureate Shinya Yamanaka, whose identification of induced pluripotent stem cells (iPSCs) revolutionized regenerative medicine, underscored the transformative potential of reprogramming adult cells to a pluripotent state. This discovery laid the groundwork for novel approaches in personalized disease models and cell replacement therapies that continue advancing toward clinical application.

Another highlight included Madeline Lancaster’s presentation on brain organoids—three-dimensional cultures derived from stem cells that recapitulate human brain development. These models are invaluable for probing complex neurodevelopmental processes and uncovering mechanisms underlying neurological disorders, offering unprecedented insights into human brain evolution and pathology.

Yukiko Gotoh’s research shed light on the molecular circuits guiding neuronal specification and connectivity formation during mammalian brain development. Her findings contribute to an enhanced understanding of neurodevelopmental disorders, elucidating how disruptions to these pathways may lead to cognitive and behavioral phenotypes.

Feng Zhang, renowned for pioneering CRISPR genome-editing technologies, discussed innovations that enhance the precision and scope of genetic engineering in stem cell contexts. Such advancements open avenues for sophisticated gene-modulation therapies targeting neurological diseases, paving the way for personalized, cell-based interventions.

Throughout the conference, participants engage with state-of-the-art tools and emerging technologies showcased in the Exhibit and Poster Hall, offering a glimpse into next-generation platforms that promise to accelerate both basic research and clinical translation.

President Okano emphasized the ISSCR community’s shared commitment to advancing science responsibly, ensuring that transformative discoveries are ethically developed for global patient benefit. As stem cell science rapidly evolves, ISSCR 2026 exemplifies a critical nexus for innovation, dialogue, and collaboration essential to realizing the therapeutic promise of regenerative medicine.

For more details on the ISSCR 2026 meeting, visit www.isscr2026.org.

Subject of Research: Stem cell research, regenerative medicine, gene editing, neurodevelopmental biology
Article Title: ISSCR 2026 Unites Leading Minds to Drive Forward Stem Cell Science and Translational Innovation
News Publication Date: Not specified
Web References: www.isscr2026.org
Image Credits: ISSCR
Keywords: Stem cell research, regenerative medicine, induced pluripotent stem cells, brain organoids, CRISPR, neurodevelopment, translational medicine

At the heart of this innovative approach lies the CRISPR/Cas13d system, a member of the CRISPR family that specializes in targeting and cutting specific RNA sequences rather than DNA. Unlike its more widely known counterpart Cas9, Cas13d carries the unique ability to modulate RNA transcripts transiently without permanently altering the genome, a feature that enhances safety and precision in therapeutic applications. However, delivering and activating this molecular machinery in deep tissue environments has remained a formidable technical challenge, largely due to the limited penetration of traditional activation methods like ultraviolet or visible light.

To overcome these obstacles, the research team has exploited the remarkable properties of upconversion nanoparticles (UCNPs), which can convert near-infrared (NIR) light—capable of penetrating several centimeters into biological tissues—into higher-energy ultraviolet or visible light that can trigger the activation of CRISPR/Cas13d. This dual-functionality allows the Cas13d system to remain dormant until illuminated by a finely controlled NIR source, providing a high degree of spatiotemporal regulation crucial for minimizing off-target effects and enhancing therapeutic precision.

The engineering of these UCNPs involves doping rare-earth elements into a nanocrystal lattice, enabling them to absorb low-energy NIR photons and emit photons of higher energy through a multiphoton absorption process. These nanoparticles are conjugated with Cas13d molecules equipped with photosensitive groups that respond specifically to the emitted light, effectively ‘switching on’ the RNA-targeting activity only upon light stimulation. This system thereby forms an optogenetic-like platform tailored for non-genomic manipulation deep within tissues, an achievement not previously attained with CRISPR technologies.

In the context of orthopedic therapy, this technology offers compelling advantages. The ability to selectively regulate RNA molecules in bone, cartilage, and other connective tissues could enable precise modulation of pathways involved in inflammation, regeneration, and cellular differentiation. Traditional systemic treatments lack this level of specificity, often leading to widespread side effects or insufficient efficacy due to poor tissue penetration. By contrast, this photoactivatable platform facilitates localized therapeutic interventions that harness endogenous cellular machinery to correct pathological gene expression patterns in situ.

Moreover, the study presents detailed in vivo experiments demonstrating the efficacy of this system in animal models of bone injury and degenerative joint disorders. The researchers have shown that after systemic administration of the UCNP-Cas13d complex, targeted irradiation with NIR light successfully activates Cas13d in deep skeletal tissues, leading to significant downregulation of pathological RNA transcripts while sparing surrounding healthy cells. These findings indicate a promising route toward clinical translation, addressing a critical unmet need in treating orthopedic diseases resistant to conventional therapies.

A defining feature of this approach is the reversibility and temporal control afforded by light-activated modulation. Unlike permanent genomic edits, the transient nature of RNA targeting preserves the dynamic regulation of gene expression necessary for normal physiological processes. This is particularly relevant in orthopedic tissues that undergo continuous remodeling and repair, requiring finely tuned molecular interventions that can be turned on or off as needed.

Furthermore, the safety profile of this system benefits greatly from the use of NIR light, which poses minimal phototoxicity and penetrates tissues with less scattering and absorption compared to ultraviolet or visible light. This attribute enhances patient comfort and reduces risks associated with repeated treatments, making the technology well-suited for clinical protocols involving chronic or repeated dosing.

Beyond orthopedics, the implications of this technique extend broadly across biomedical research and therapy. Deep-tissue RNA engineering facilitated by non-invasive photoactivation could revolutionize treatments for neurological disorders, cardiovascular diseases, and various cancers where localized, precise control of gene expression is critical. The modular nature of the UCNP-Cas13d system allows adaptation to a myriad of RNA targets, underscoring its potential as a versatile platform for precision medicine.

The study also addresses critical challenges in nanoparticle delivery and biocompatibility. Special attention has been paid to optimizing the size, surface chemistry, and stability of the UCNPs to evade immune clearance and minimize toxicity. In vivo imaging and biodistribution analyses confirm efficient accumulation in target tissues with minimal retention in off-target organs, enhancing the therapeutic index and reducing adverse effects often associated with nanoparticle-based delivery systems.

Technically, the researchers have implemented sophisticated optical setups capable of delivering spatially confined NIR light pulses, enabling selective activation of the CRISPR/Cas13d complex in defined regions. This capacity for high-resolution irradiation could be further refined using advanced light delivery techniques such as fiber optics or implantable devices, expanding the clinical versatility of the platform.

Importantly, the RNA-targeting specificity of Cas13d coupled with the light-dependent activation mitigates the risk of unintended gene silencing or collateral damage to non-target tissues. Such precision is vital for therapies aimed at tissues with complex, delicate microenvironments like cartilage and bone marrow, where indiscriminate intervention could disrupt essential physiological processes.

The researchers have also provided extensive molecular characterization of the photoactivation mechanism, detailing the conformational changes in Cas13d upon light exposure facilitated by UCNP emission. This mechanistic insight is crucial for rational design improvements and offers a foundation for future enhancements that could improve activation efficiency, reduce latency, or expand wavelength responsiveness.

Moving forward, the team envisions integration of this technology with other therapeutic modalities such as stem cell transplantation or biomaterial scaffolds to synergistically enhance tissue regeneration. The ability to program RNA expression during these interventions using light adds a powerful layer of control, potentially accelerating recovery and improving functional outcomes.

Overall, this pioneering work sets a precedent for combining nanotechnology, optogenetics, and CRISPR platforms to achieve previously unattainable precision in RNA therapeutics. Its applications in orthopedic therapy represent just the beginning as the technology matures and moves closer to clinical deployment, promising a new era of minimally invasive, highly adaptable gene-editing treatments that operate safely and effectively within the deepest reaches of our tissues.

The breakthrough demonstrated by Zhao, Zhang, Gao, and colleagues marks a turning point in the translation of genetic tools from bench to bedside—bringing us closer to a future where debilitating orthopedic conditions can be managed or even cured through targeted RNA engineering controlled merely by light. This confluence of disciplines exemplifies the power of interdisciplinary innovation in reshaping medicine for generations to come.

Subject of Research: Photoactivatable CRISPR/Cas13d system for deep tissue RNA engineering and orthopedic therapy using upconversion nanoparticles.

Article Title: Photoactivatable CRISPR/Cas13d via upconversion nanoparticles for deep tissue RNA engineering and orthopedic therapy.

Article References:
Zhao, J., Zhang, J., Gao, M. et al. Photoactivatable CRISPR/Cas13d via upconversion nanoparticles for deep tissue RNA engineering and orthopedic therapy. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72181-6

Image Credits: AI Generated

Over the past five years, stem cell research has experienced rapid and transformative growth, driven by technological innovations and novel experimental models. The podcast has been at the forefront of disseminating these developments globally, establishing a broad reach with episodes downloaded in 139 countries. This profound engagement within the scientific community highlights the podcast’s pivotal role in fostering dialogue and knowledge exchange among researchers, clinicians, and stakeholders committed to translating stem cell discoveries into therapeutic realities.

Janet Rossant, Ph.D., Editor-in-Chief of ISSCR’s Stem Cell Reports and host of the podcast, reflects on this journey, emphasizing the evolution of both the podcast and the field. She credits the founding leadership of Martin Pera, Ph.D., whose vision shaped the podcast into a forum for deep, insightful conversations that have captured emerging trends and milestone achievements. The anniversary episode acts as a reflective lens, bringing together influential voices in the field to revisit pioneering research endeavors and assess their impact over half a decade.

Noteworthy is the guest roster for this commemorative episode, featuring acclaimed scientists such as Lawrence Goldstein, Ph.D., formerly of the University of California San Diego; Charles Murry, M.D., Ph.D., from the University of Southern California; Clare Parish, Ph.D., affiliated with The Florey Institute of Neuroscience and Mental Health and the University of Melbourne; and Martin Pera, Ph.D., currently at The Jackson Laboratory. Their collective expertise spans key areas of stem cell research including neurobiology, cardiac regeneration, and advanced modeling systems, providing a comprehensive perspective on the field’s trajectory.

The dialogue delves into the early stages of their respective research programs, contrasting initial hypotheses and technological capabilities with today’s sophisticated methodologies. From the advent of induced pluripotent stem cells (iPSCs) to the refinement of organoid systems that recapitulate human tissue architecture, these scientists dissect landmark accomplishments and delineate the challenges that remain. Advances in organoid technology, for instance, have revolutionized disease modeling by enabling multi-dimensional, physiologically relevant systems capable of mimicking complex developmental processes and pathologies in vitro.

Furthermore, the conversation addresses the rigorous establishment of global standards concerning experimental reproducibility, scientific ethics, and data transparency. As stem cell therapies edge closer to clinical application, adherence to these principles is paramount to ensure patient safety and the integrity of translational research. The podcast underscores how coordinated international efforts have fostered a cohesive framework—a necessary foundation to navigate ethical concerns, regulatory scrutiny, and public trust.

Several past episodes have resonated strongly with listeners, emphasizing the diverse and interdisciplinary nature of stem cell research. Topics spanning X-chromosome inactivation dynamics, the generation and application of blastoids and gastruloids as embryonic models, mechanistic insights into somatosensory biology, and evaluations of ongoing clinical trials are highlighted for their scientific depth and societal relevance. These discussions offer unparalleled insights into how foundational research informs therapeutic innovation and provides a critical understanding of human development and disease.

Importantly, the podcast revisits pivotal themes such as Parkinson’s disease cell therapy, the complex legacy of human fetal tissue research, and cardiac tissue regeneration. These topics illustrate the longitudinal progress in stem cell biology, reflecting both scientific persistence and the incremental translation of basic discoveries into potential treatments. By contextualizing decades of research through a contemporary lens, the podcast equips listeners with a nuanced appreciation for the scientific rigor and creative problem-solving driving the field forward.

Central to the podcast’s mission is the dissemination of knowledge that bridges basic science with clinical aspirations. The Stem Cell Report has successfully intertwined narratives of molecular breakthroughs with personal stories of researchers, fostering a community dedicated to the responsible and innovative use of stem cells. The resulting discourse not only educates but also inspires current and future scientists, policymakers, and the broader public about the transformative possibilities of stem cell science.

This special anniversary episode underscores a compelling vision: stem cell research is not a static scientific pursuit but a continuously evolving domain marked by collaboration, innovation, and ethical stewardship. The dynamic interplay between cutting-edge laboratory research and emerging clinical applications reinforces the field’s promise to address some of the most intractable health challenges, from neurodegeneration to organ failure.

Listeners and interested parties are encouraged to explore the full collection of podcast episodes via multiple platforms including Spotify, Apple Podcasts, and direct downloads on the ISSCR website. This open-access approach exemplifies the society’s commitment to broadening access to scientific discourse and accelerating the translation of stem cell science into tangible health benefits.

Beyond celebrating past achievements, “Stem Cell-ebration” serves as a clarion call for sustained investment, interdisciplinary collaboration, and creative inquiry. As the field continues to navigate complexities ranging from cellular heterogeneity to immune compatibility, these conversations illuminate strategic pathways for maximizing the impact of stem cell research in personalized medicine and regenerative therapeutics.

Looking forward, the podcast anticipates chronicling emerging paradigms such as gene editing integration with stem cell platforms, advanced biomaterials for tissue engineering, and the exploitation of single-cell omics to unravel cellular complexity. The next chapters in this narrative will undoubtedly demand the same scientific rigor, ethical mindfulness, and visionary thinking that have propelled the journey so far.

In essence, the ISSCR’s The Stem Cell Report podcast epitomizes a vibrant scientific dialogue, one that is simultaneously reflective, informative, and forward-looking. It not only documents the past five years of revolutionary progress but also illuminates the boundless horizons ahead, where stem cell science holds profound potential to redefine medicine and human health on a global scale.

Subject of Research: Stem Cell Research and Regenerative Medicine

Article Title: Stem Cell-ebration: Five Years of Breakthrough Science and Insightful Conversations in Stem Cell Research

News Publication Date: Not explicitly stated

Web References:

• The Stem Cell Report Podcast: https://thestemcellreport.buzzsprout.com/1661578
• ISSCR: https://www.isscr.org
• Stem Cell Reports Journal: https://www.cell.com/stem-cell-reports/home

Image Credits: ISSCR

Keywords: Stem Cell Research, Regenerative Medicine, Organoids, Induced Pluripotent Stem Cells, Translational Research, Scientific Communication, Stem Cell Therapy, Disease Modeling, Clinical Trials, Scientific Ethics, Reproducibility, Stem Cell Reports, ISSCR

Historically, scientific inquiry into limb regeneration centered predominantly on amphibians, known for their extraordinary regenerative abilities, leaving mammalian models less explored. Despite sharing a significant overlap in genes associated with regeneration, mammals do not replicate the full limb regrowth seen in amphibians. The critical question remained: do mammalian tissues retain a dormant regenerative potential that is simply suppressed, or is regeneration fundamentally unattainable in these species due to evolutionary divergence?

To address this, the team led by Can Aztekin undertook a comparative experimental approach involving frog tadpoles and developing mouse embryos. By amputating limbs and observing their regeneration under controlled oxygen environments, the researchers sought to tease apart the role of oxygen from other ecological and physiological factors. They meticulously adjusted oxygen levels to mimic the relatively low oxygen availability in aquatic environments typical for amphibians, or elevated levels comparable to mammalian tissues exposed to atmospheric oxygen.

The cellular responses under these conditions were striking. In mouse embryonic limbs, reducing oxygen concentrations accelerated wound closure and activated cellular behaviors reminiscent of regenerative processes. This activation included enhanced cellular motility, metabolic shifts favoring glycolysis— a pathway adapted for low oxygen—and epigenetic modifications conducive to gene expression necessary for regeneration. Interestingly, artificially stabilizing a key oxygen-sensing protein called HIF1A under normal oxygen conditions mimicked the effects of hypoxia, suggesting the protein’s central role in controlling the cellular switch between healing and regeneration.

Conversely, frog tadpoles exhibited robust limb regeneration irrespective of oxygen variations, even at oxygen levels exceeding those found in air. Molecular analyses revealed that these amphibians maintain stable HIF1A activation despite increased oxygen, partly due to lowered expression of genes responsible for deactivating the hypoxia response. This resilience indicates an evolutionary adaptation that decouples their regenerative capability from fluctuating oxygen availability, contrasting sharply with the oxygen-sensitive regenerative pathways observed in mammals.

Extending their analysis across multiple vertebrate species including axolotls and humans, the researchers uncovered a consistent evolutionary pattern. Regeneration-competent amphibians display attenuated oxygen sensing pathways, facilitating persistent activation of regenerative programs post-injury. Mammalian cells, however, respond vigorously to oxygen, rapidly switching off regenerative pathways after wounding, and favoring scar formation instead. This fundamental biological divergence underscores oxygen sensing as a critical determinant in regenerative potential beyond genetic programming alone.

These findings that mammalian embryonic tissues harbor a latent capacity for regeneration—hindered by their oxygen sensing mechanisms—introduce a paradigm shift in regenerative biology. It implies that therapeutic strategies targeting oxygen sensing pathways, and specifically modulating HIF1A stability, could unlock regenerative abilities suppressed in adult mammals. Such breakthroughs hold promise for improving wound healing and possibly stimulating regeneration in human limbs, a long-sought goal in biomedical research.

Importantly, the study does not claim imminent feasibility of full limb regrowth in humans but clarifies that the early steps of regeneration can be pharmacologically induced in mammalian cells. This insight provides a tangible and testable foundation for future research to refine regenerative medicine techniques, focusing on the interplay between environmental sensing and cellular reprogramming.

By deploying advanced methodologies including live limb culture under variable oxygen tensions, combined with state-of-the-art genomic and epigenomic profiling, the research team dissected the intricate molecular landscapes governing regeneration. They demonstrated how shifts in oxygen availability translate into epigenetic remodeling that primes genes essential for regrowth, highlighting the dynamic interrelationship between external environment and intrinsic cell machinery.

The investigation was conducted under stringent Swiss animal welfare regulations, emphasizing responsible scientific practice balanced with the potential transformative impact of the research. Collaborations spanned multiple institutions worldwide, leveraging expertise in bioengineering, bioinformatics, and molecular biomedicine, underscoring the multidisciplinary effort required to unravel this complex biological phenomenon.

This landmark discovery not only advances fundamental understanding of vertebrate biology but also inspires a new wave of research exploring how manipulation of oxygen-related pathways can facilitate regeneration in organisms traditionally viewed as non-regenerative. The implications stretch far beyond limbs, potentially influencing healing paradigms across multiple tissues and organs affected by injury or disease.

The work by Can Aztekin and colleagues effectively bridges ancient biological mysteries with modern scientific innovation, bringing us closer to unlocking innate regenerative capacities that could one day revolutionize human medicine. It is a compelling reminder that evolutionary biology and environmental factors remain critically entwined in defining physiological capabilities across species.

Subject of Research: The influence of species-specific oxygen sensing mechanisms on the initiation of vertebrate limb regeneration.

Article Title: Species-specific oxygen sensing governs the initiation of vertebrate limb regeneration

News Publication Date: 9-Apr-2026

Web References:

• DOI Link to Article
• EPFL Aztekin Lab

References:
Georgios Tsissios, Marion Leleu, Kelly Hu, et al. “Species-specific oxygen sensing governs the initiation of vertebrate limb regeneration.” Science, 09 April 2026. DOI: 10.1126/science.adw8526

Keywords: Limb regeneration, oxygen sensing, HIF1A, vertebrate regeneration, amphibians, mammals, epigenetics, wound healing, metabolic reprogramming, regenerative biology, hypoxia, cellular oxygen sensor

The human skin is a perpetual frontline defender, vulnerable to constant physical insults yet remarkably adept at healing minor wounds in days under optimal conditions. However, in clinical populations such as the elderly and diabetics, skin repair is markedly impaired, often resulting in chronic wounds that resist treatment and severely impact quality of life. Addressing this unmet clinical need, the research team led by Professor Sekyu Choi has pioneered a strategy that does not demand a full reset of cells, which is historically linked to deleterious risks including tumorigenesis due to uncontrolled cell growth.

Instead, their innovative approach employs partial cellular reprogramming targeted to only a portion of the epidermal cell population. By introducing the well-known Yamanaka transcription factors—Oct4, Sox2, Klf4, and c-Myc—but in a controlled and restrained manner, these cells are nudged back into a youthful, pre-regenerative state without complete dedifferentiation. This partial rewind ensures the preservation of essential cell identity and function, circumventing the malignant transformation pitfalls often observed with full reprogramming.

Remarkably, this “mosaic” pattern of cellular intervention uses intercellular communication to broadcast a pre-emptive alert throughout the skin tissue. The epidermis as a whole enters what the researchers describe as a “pre-regenerative mode,” even in the absence of any immediate injury. Surrounding unaltered keratinocytes, immune cells, and local stromal components respond dynamically, reorganizing their behaviors and interactions within the microenvironment to brace for forthcoming damage.

Central to this orchestrated molecular symphony is the activation of pivotal signaling cascades such as the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, epidermal growth factor receptor (EGFR) signaling, and hypoxia-inducible factor 1-alpha (HIF-1α) pathways. These pathways collaborate to bolster cell survival, stimulate proliferation, and promote adaptation to low oxygen tension—conditions typically seen in wounded tissue—thereby preconditioning the skin for enhanced reparative capacity.

When injuries were subsequently inflicted in experimental animal models, this primed epidermis exhibited dramatically accelerated wound closure. Enhanced epithelial migration formed new skin layers at an expedited rate, vascular regeneration was precisely coordinated to support the healing tissue, and immune responses were optimally balanced to prevent excessive inflammation and scarring. Such outcomes were profoundly significant given that these benefits held true even within diabetic models, which notoriously experience delayed and complicated wound healing.

The implications of this research extend far beyond wound repair. By demonstrating that manipulating only a minority of cells within a tissue can recalibrate the entire organ’s regenerative potential, this study opens a pivotal frontier for anti-aging interventions and biomaterial engineering. The ability to elevate tissue homeostasis proactively, without the risks associated with complete cellular reprogramming, charts a promising path toward safer and more effective regenerative therapies.

Professor Choi emphasizes the novelty of their discovery, stating that this is the first instance highlighting how partial cellular reprogramming can remodel the behavior of neighboring cells and microenvironmental niches through complex intercellular signaling networks. This insight fundamentally challenges existing paradigms, which largely view reprogramming as an all-or-nothing event, instead advocating for more nuanced, mosaic-level interventions.

First author Minjun Kwak envisions broad translational applications of their findings, suggesting that this strategy might form the backbone of next-generation treatments for persistent wounds, particularly in vulnerable populations like diabetics and the elderly. Moreover, the concept of preemptively enhancing tissue resilience holds remarkable potential for the design of regenerative medicines and smart biomaterials capable of dynamic interactions with host tissues.

The diligent work was achieved through a synergistic collaboration involving institutions across South Korea and the University of Washington, supported by various governmental initiatives focusing on stem cell therapies and regenerative bioengineering. Their comprehensive approach integrated molecular biology, tissue engineering, and in vivo functional analyses to dissect the mechanistic underpinnings and therapeutic efficacy of partial epidermal reprogramming.

As the field of regenerative medicine burgeons, this study sets a compelling precedent by illustrating the feasibility and promise of gentle, selective cellular reprogramming. By fine-tuning the balance between cellular plasticity and identity, scientists can unlock regenerative potential hidden within mature tissues while mitigating risks—a paradigm shift that could redefine how we approach healing and aging at the cellular level.

This research not only illuminates the intricate dance between cells within the skin but also inspires a vision for regenerative interventions that parallel natural physiological processes, thereby ensuring safety and maximizing therapeutic impact. The concept of preparing the skin in advance, akin to students studying before an exam, might soon be the key to winning the battle against non-healing wounds worldwide.

Subject of Research: Partial reprogramming of skin epidermal cells to enhance wound healing and tissue homeostasis.

Article Title: Mosaic partial epidermal reprogramming remodels neighbors and niches to refine skin homeostasis and repair

News Publication Date: 30-Jan-2026

Web References: 10.1038/s41467-026-69047-2

Image Credits: POSTECH

Keywords: Life sciences, Regeneration, Skin regeneration, Physiology, Tissue repair, Wound healing, Keratinocytes, Skin cells, Cellular reprogramming, Morphogenesis, Immune regulation, Regenerative medicine

Stem cell transplants have traditionally been hindered by the host immune system’s aggressive response to foreign cells, leading to rejection episodes that necessitate chronic immunosuppression. This practice carries significant adverse effects, including heightened vulnerability to infections and malignancies. Overcoming this immunological barrier has remained the elusive holy grail in cell therapy. Professor Danny Chan and his team, leveraging genomic editing tools alongside insights drawn from unique biological phenomena, have now developed a stem cell line capable of ‘cloaking’ itself from immune surveillance, thus heralding a new era of universal donor cells.

The inspiration for creating these immune-evasive cells derived from natural models of immune evasion, among which transmissible cancers in Tasmanian devils stand out. These cancers circumvent host immunity by disguising themselves, allowing malignant cells to take root in genetically disparate individuals. Similarly, the human placenta exhibits remarkable immune tolerance, maintaining harmonious coexistence between genetically distinct maternal and fetal tissues. Furthermore, certain human cancers actively suppress immune cells in their microenvironment, enabling unchecked growth. Integrating these mechanisms, the research team engineered stem cells that invisibly camouflage from immune detection while concurrently exerting localized immunosuppressive effects to protect adjacent tissues.

The engineered FailSafe-AlloAccept stem cells underwent rigorous preclinical testing using humanised immune system mice, which faithfully recapitulate the complexities of the human immune response. Remarkably, unmodified embryonic stem cells were rapidly identified and cleared by the host immune system, preventing successful engraftment. Contrastingly, FailSafe-AlloAccept cells thrived, generating viable tissues sustained for up to five months post-transplantation without observable rejection. This outcome underscores the cells’ extraordinary capacity to achieve immune acceptance across diverse genetic backgrounds, a landmark achievement in the field.

Critically, the immune cloaking mechanism does not jeopardize the recipient’s overall immune competence. Mice with FailSafe-AlloAccept grafts retained full immunocompetence, efficiently rejecting foreign invaders and neoplastic cells not cloaked by the engineered cells. This facet is essential to guarantee that immune evasion by therapeutic grafts does not induce systemic immunodeficiency, which could otherwise predispose patients to severe infections or secondary tumors. Such precision in modulating immune interactions marks an unprecedented sophistication in cellular engineering.

Given the inherent risk of tumorigenesis fueled by mutations accumulated during repeated cell divisions, the research incorporated an ingenious kill switch. This genetic safety net enables selective eradication of any proliferating aberrant cells via administration of a common, clinically approved drug, providing a crucial safeguard before clinical translation. Professor Andras Nagy emphasized that this integrated security element elevates the therapeutic potential by simultaneously addressing efficacy and patient safety—two non-negotiable pillars for viable cell-based therapies.

The implications of this technology resonate beyond individual diseases. Conditions lacking curative options—Parkinson’s disease, type 1 diabetes, heart failure, and spinal cord injuries—stand to benefit from ready availability of safe, high-quality stem-cell derived tissues tailored through this universal platform. Importantly, this approach could eliminate the pressing shortage of donor organs and cells while obviating chronic immunosuppressive regimens that plague current transplant recipients with debilitating side effects.

This pluripotent cell line’s versatility is remarkable. Their pluripotency means these stem cells can be differentiated into virtually any cell type required for tissue regeneration, ranging from neurons to pancreatic islets and cardiomyocytes. The ability to generate therapeutic doses of cells on demand, combined with immune invisibility, paves the way for scalable manufacturing of standardized, banked cell therapy products accessible worldwide irrespective of patient HLA compatibility.

Beyond the laboratory, the scientific partnership forged across the Pacific signifies a paradigm for collaborative innovation. Hinged on the Distinguished Visiting Scholar Scheme, the synergy between Professor Chan’s lab at HKUMed and Professor Nagy’s team in Toronto exemplifies how international cooperation can catalyze disruptive advances with global health impact. Their unified expertise in stem cell biology, immunology, and genomic engineering has generated a pioneering solution set to accelerate clinical translation timelines.

As preclinical validation progresses, the research community anticipates subsequent human trials that will rigorously evaluate long-term safety and therapeutic efficacy. While challenges remain—including scalability, regulatory approval, and comprehensive immune profiling—the FailSafe-AlloAccept cells represent a monumental step toward universal cell therapies that could replace traditional transplantation entirely. If successful, these innovations promise to revolutionize the treatment landscape for millions of patients worldwide, unlocking new frontiers in personalized and regenerative medicine.

In summary, the creation of genetically cloaked, safe human pluripotent stem cells equipped with a fail-safe kill mechanism addresses two of the greatest obstacles in transplantation medicine: immune rejection and tumorigenic risk. By drawing on nature’s immune evasion strategies and combining them with cutting-edge genome editing, this technology might soon enable off-the-shelf regenerative therapies without the need for chronic immunosuppression, profoundly altering the future of medicine.

Subject of Research: Not applicable

Article Title: Genome-edited safe and immune-evasive human pluripotent cells: Potential solution for allogeneic therapies

News Publication Date: 5-Mar-2026

Web References:

• Stem Cell Reports Publication
• DOI: 10.1016/j.stemcr.2026.102850

Image Credits: The University of Hong Kong

Keywords

Immune evasion, pluripotent stem cells, genome editing, regenerative medicine, allogeneic transplantation, cellular immunology, tumorigenesis prevention, universal donor cells, stem cell therapy, translational research, collaborative innovation, off-the-shelf therapies

The essence of this pioneering approach lies in the concept of ‘developmental engineering,’ a strategy that draws direct inspiration from the intricate orchestration of kidney organogenesis in vivo. The embryonic kidney accomplishes an astonishing complexity through coordinated spatial and temporal cues, yielding highly ordered and functional tissues composed of diverse cell types working in concert. By emulating these developmental blueprints, scientists aim to impose precise control over the microenvironment and patterning signals that guide human pluripotent stem cells toward renal lineages, enabling the in vitro construction of kidney tissue with enhanced fidelity and function.

At the core of this developmental engineering method is the deliberate manipulation of initial and boundary conditions, an aspect often overlooked in conventional tissue culture systems. By leveraging modern synthetic biology tools alongside advanced biofabrication techniques, researchers can now create engineered niches that provide spatial patterning cues and temporal feedback signals reminiscent of the embryonic milieu. These controlled microenvironments potentiate the self-organization processes inherent to nephrogenesis, ultimately yielding complex tissue motifs that encapsulate essential renal features such as nephron segments, vasculature, and interstitial components.

One of the nuanced challenges this study addresses involves the intrinsic heterogeneity and stochasticity of stem cell differentiation. Traditional protocols yield variable outcomes, producing immature or incomplete kidney tissues. In contrast, the developmental engineering framework strategically leverages synthetic gene circuits and signaling pathway modulators to synchronize cell fate decisions, thus reducing variability and promoting a more uniform maturation trajectory. This deliberate orchestration offers an elegant solution to previously intractable barriers, pushing the envelope of in vitro kidney tissue complexity and functionality.

Moreover, the research introduces the concept of ‘motif chaining,’ a visionary approach that bridges discrete tissue self-organization events to achieve higher-order tissue assembly. In embryogenesis, multiple kidney progenitor niches differentiate and interact concurrently, enabling organ-scale architecture and function. Mimicking this, developmental engineering integrates modular tissue units or motifs via engineered interfaces and spatial cues. This daisy-chaining process overcomes physical and developmental discontinuities that have historically limited the scalability and organization of synthetic tissues, heralding a new paradigm in organoid engineering.

Importantly, the implications of this development extend beyond nephrology and renal replacement therapies. The methodology presents a broadly applicable framework for synthetic biology and tissue engineering across a spectrum of solid organs. Organs such as the liver, lung, and pancreas, which also depend on finely tuned developmental processes and multi-lineage interactions, stand to benefit from this interdisciplinary synthesis of developmental biology and bioengineering. This paves the way for future organ reconstruction strategies that are scalable, clinically translatable, and capable of restoring complex organ functions.

To realize this ambitious goal, the study underlines the vital role of interdisciplinary integration encompassing stem cell biology, synthetic biology, developmental signaling, and biomaterials science. The emergent tools highlighted include gene editing systems that program intracellular signal transduction, spatial patterning technologies such as microfluidic gradient generators, and biomimetic scaffolds that simulate native extracellular matrices. These innovations together establish a set of elevated boundary conditions and instructive cues that guide stem cells through precise, developmentally inspired trajectories.

Critically, the developmental engineering framework reconsiders the role of self-organization. Rather than relying solely on spontaneous morphogenesis, the approach uses engineered constraints and signals to ‘steer’ and synchronize developmental programs. This shifts the paradigm from uncontrolled organoid variability towards predictable and reproducible tissue morphogenesis. Consequently, this manipulation anticipates a future where bioengineered kidney constructs possess not only correct cell types and tissue architecture but also demonstrate vascular perfusion, renal filtration, and metabolic capabilities mirroring native kidneys.

In addition to functional integration, the scalability of tissue production represents a cornerstone of clinical translation. The study articulates strategies for upscaling developmental engineering by iteratively expanding and chaining tissue motifs, thus amplifying tissue size while preserving developmental cues and patterning fidelity. Advances in automated biofabrication and bioreactor design synergize with this approach, promising robust manufacturing pipelines that meet clinical demand for renal replacement tissues.

Furthermore, this developmental engineering blueprint embodies a precision medicine ethos. By recapitulating patient-specific developmental pathways via induced pluripotent stem cells (iPSCs), the technology could produce personalized kidney tissues that minimize immune rejection risks and enhance therapeutic outcomes. The capacity to tailor developmental cues and synthetic circuits to individual genetic backgrounds holds transformative potential for personalized regenerative interventions and disease modeling platforms.

Despite its promise, the study acknowledges ongoing challenges, including the need to refine vascularization, innervation, and immune system integration within engineered kidney tissues. Future research will likely harness emerging technologies such as multi-omics profiling, machine learning-guided differentiation optimization, and in vivo transplantation studies to address these gaps. Continuous refinement of synthetic biology tools and microenvironmental engineering will remain critical to advancing developmental engineering from experimental proof-of-concept to clinical reality.

In summation, this visionary developmental engineering strategy charts a new course for synthetic kidney tissue fabrication by embedding developmental principles into engineering workflows. It combines cutting-edge synthetic biology, spatial-temporal patterning, and microenvironmental control to reprogram stem cells into complex, functional kidney motifs that can be scaled and assembled into higher-order structures. By doing so, it transcends current limitations in organoid technology, aligning biofabrication more closely with nature’s blueprint for organ development.

The research not only propels the renal regeneration field towards feasible therapeutic applications but also sets a precedent for engineering complex tissues across biomedicine. As developmental engineering tools mature and integrate with next-generation biofabrication platforms, the horizon opens towards clinically relevant, robustly functional bioengineered organs—transforming the landscape of organ failure treatment and regenerative medicine.

This comprehensive developmental engineering framework offers a tangible pathway to resolve longstanding challenges in kidney tissue engineering. Through meticulous orchestration of spatial cues, temporal signals, and synthetic regulatory circuits, it harnesses the logic of embryonic development to create viable renal tissues in vitro. The anticipated impact spans from advancing fundamental developmental biology understanding to realizing scalable clinical solutions for patients suffering from kidney diseases worldwide.

In essence, this approach symbolizes a paradigm shift, moving beyond passive organoid culture towards active design and control of organogenesis-inspired tissue formation. As researchers and clinicians continue to refine and adopt these strategies, the dream of synthetic, functional kidney replacements transitions from science fiction to imminent reality, potentially revolutionizing patient care in nephrology and beyond.

Subject of Research:
Stem cell-derived kidney tissue engineering inspired by embryonic development processes.

Article Title:
Developmentally inspired synthetic kidney engineering

Article References:
Warrner, E., Huang, A.Z. & Hughes, A.J. Developmentally inspired synthetic kidney engineering.
Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03011-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-026-03011-9

The study, recently published in the esteemed journal Stem Cells, details the derivation of pluripotent stem cells from bovine blastocysts—an early embryonic stage characterized by a fluid-filled cavity surrounded by a cluster of cells primed for uterine implantation. Exploiting this pivotal developmental window, the research team meticulously cultured these pluripotent cells using mouse feeder layers supplemented with a precisely formulated culture medium designed to sustain the cells’ formative pluripotent state in vitro. This approach marked a substantial advancement over prior attempts, which often failed to maintain the delicate balance necessary to preserve pluripotency in bovine cells.

Central to this breakthrough is the creation of a customized culture medium fortified with a cocktail of small molecule supplements tailored explicitly to bovine cellular physiology. Unlike stem cells from other species, bovine pluripotent stem cells require a distinct biochemical environment to maintain their undifferentiated status. Recognizing this, the investigators designed a basal medium modified with additional growth factors and signaling molecules, overcoming a significant bottleneck that has historically hindered the development of stable bovine embryonic stem cell lines.

One of the most competitive advantages of this novel cell line lies in its advanced plasticity. According to Jiaxi Liu, a key member of the team, these formative embryonic stem cells exhibit the capability to directly induce primordial germ cell-like cells (PGCLCs), which are crucial precursors to gametes—sperm and eggs. This capability suggests not only profound implications for animal breeding and conservation but also opens new avenues for comprehensive in vitro gametogenesis studies, a cutting-edge frontier in reproductive biology.

Importantly, the approach builds upon Tian’s previous work with induced pluripotent stem cells (iPSCs) derived from bovine somatic cells, an innovation that reprogrammed differentiated cells to a pluripotent state using genetic engineering methods. However, embryonic stem cells cultured from the embryo itself carry a distinct regulatory and safety advantage—they are free from foreign genetic modifications, an essential criterion for their potential use in applications such as cultivated meat, where regulatory agencies remain cautious about genetically modified organisms.

This embryonic stem cell line represents a significant stride towards producing clean, genetically unaltered pluripotent lines that circumvent the prolonged and sometimes inefficient process of cellular reprogramming inherent in iPSC technology. The direct derivation also reduces inter-line variation, streamlining subsequent applications, from basic developmental biology studies to commercial-scale cellular agriculture.

The implications for cultivated meat technology are particularly exciting. By guiding these pluripotent stem cells to differentiate into muscle and adipose (fat) cells, researchers envision scalable, animal-free meat production systems capable of producing sustainable, ethically sourced beef products. Such lab-grown meat addresses mounting global concerns about the environmental footprint and animal welfare issues tied to traditional livestock farming, potentially reshaping the future of food security worldwide.

Beyond agricultural applications, these stem cells serve as invaluable platforms for medical research. They provide robust, large-animal models for studying human diseases, facilitating drug discovery, and antibody screening with greater physiological relevance. The larger size and different developmental trajectories of bovine cells compared to typical rodent models present an unparalleled system for exploring complex tissue regeneration and replacement strategies potentially translatable to human medicine.

Despite remarkable progress, the UConn team is actively pursuing further innovations. One critical next step involves eliminating the reliance on mouse feeder cells for stem cell maintenance—a necessary shift to make the technology viable for commercial cultivation and clinical applications. The removal of xenogeneic feeder layers demands the development of fully defined, feeder-free culture systems that still preserve cell viability and pluripotency, a challenge Tian’s laboratory is tackling with customized extracellular matrix coatings and optimized culture media compositions.

In parallel, efforts are underway to engineer culture media formulations that extend stem cell maintenance intervals without daily medium changes, significantly reducing resource consumption and environmental waste—a vital consideration for sustainability in large-scale bioprocesses. The goal is to develop a “weekender medium,” a robust culture environment supporting long-term cell growth and division, thus lowering operational costs for potential industrial applications.

The team’s work has garnered support from UConn’s Technology Commercialization Services (TCS), which is actively assisting in protecting intellectual property rights via patent filings for the newly developed embryonic stem cell line and associated culture technologies. This partnership facilitates pathways towards commercialization and collaboration with industry stakeholders, accelerating translation from laboratory discovery to market-ready biomedical and bioindustrial solutions.

Further amplifying the impact, the bovine ESC line is being integrated with The Good Food Institute’s global repository of cell lines for cultured meat research. This inclusion is expected to bridge existing gaps in available cell culture platforms, propelling both academic and industrial research towards efficient and reproducible lab-grown meat products. The precedent set by the widespread distribution of UConn’s induced pluripotent stem cell lines worldwide signals a similarly transformative fate for these embryonic stem cells.

In summation, this innovative bovine embryonic stem cell derivation unlocks a multitude of scientific and practical possibilities. It heralds a new era of livestock biotechnology, regenerative medicine, and ethical food production, positioning the UConn team at the forefront of a rapidly evolving, multidisciplinary field with profound implications for global health, sustainability, and bioeconomy.

Subject of Research: Cells

Article Title: Bovine formative embryonic stem cell plasticity in embryonic and extraembryonic differentiation

News Publication Date: 1-Jan-2026

Web References:
http://dx.doi.org/10.1093/stmcls/sxaf068

Image Credits: Milton Levin/UConn Photo

Keywords: Cell development, Cell biology